Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

Karilyn Gower, Press Officer
w. (202) 588-7779

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


Nov. 14, 2013

Approval of Tasimelteon Would Set Dangerous Precedent, Public Citizen Tells FDA Advisory Committee

Last-Minute, Highly Unorthodox Changes to Clinical Trial Protocol for New Sleep Medicine Threaten to Undermine Integrity of Approval Process for New Drugs

WASHINGTON, D.C. – The uncertainties generated by last-minute changes to the clinical trial protocol for the new sleep medicine tasimelteon raise serious questions about the drug’s effectiveness and, if it is approved, about the U.S. Food and Drug Administration’s (FDA’s) standards for approving new drugs, Public Citizen said today in testimony to the agency’s Peripheral and Central Nervous Systems Drugs Advisory Committee.

Approximately 10 percent of the blind cannot perceive light, which often causes their circadian rhythms, and thus their sleep patterns, to periodically deviate from a normal 24-hour day. Tasimelteon would be the first drug approved to treat the estimated 100,000 blind patients with this condition, known as non-24 hour disorder.

However, the development process for tasimelteon casts considerable doubt on whether the drug is truly effective for this disorder. In a highly unusual move, almost two years into the trial and after data on most subjects had already been collected, the manufacturer of the drug, Vanda Pharmaceuticals, Inc., proposed a complete switch of the trial’s original primary endpoint for assessing the drug’s effectiveness because it claimed that it could not recruit enough subjects into the study. By the end of the trial, the FDA and the company had not agreed upon the primary effectiveness endpoint or the statistical plan used to analyze the data.

Clinical trials are designed to test a pre-specified hypothesis. Changing the analytical plan midway through a trial raises the potential for false positive findings. That tasimelteon is a new drug being tested for a new indication further increases the chances that the drug might erroneously be deemed effective.

“The way in which the data on tasimelteon were generated and analyzed raises far more questions than answers,” said Dr. Sammy Almashat, researcher with Public Citizen’s Health Research Group. “Approval of this drug, given the magnitude of post-hoc changes so close to the end of the study, would set an ominous precedent for future new drug development programs.”

Read Public Citizen’s testimony here.


Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.